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Can a Point-of-Care Troponin I Assay be as Good as a 
Central Laboratory Assay? A MIDAS Investigation
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Background: We aimed to compare the diagnostic accuracy of the Alere Triage Cardio3 
Tropinin I (TnI) assay (Alere, Inc., USA) and the PathFast cTnI-II (Mitsubishi Chemical 
Medience Corporation, Japan) against the central laboratory assay Singulex Erenna TnI 
assay (Singulex, USA).
Methods: Using the Markers in the Diagnosis of Acute Coronary Syndromes (MIDAS) 
study population, we evaluated the ability of three different assays to identify patients with 
acute myocardial infarction (AMI). The MIDAS dataset, described elsewhere, is a prospec-
tive multicenter dataset of emergency department (ED) patients with suspected acute cor-
onary syndrome (ACS) and a planned objective myocardial perfusion evaluation. Myocar-
dial infarction (MI) was diagnosed by central adjudication.
Results: The C-statistic with 95% confidence intervals (CI) for diagnosing MI by using a 
common population (n=241) was 0.95 (0.91-0.99), 0.95 (0.91-0.99), and 0.93 (0.89-
0.97) for the Triage, Singulex, and PathFast assays, respectively. Of samples with detect-
able troponin, the absolute values had high Pearson (RP) and Spearman (RS) correlations 
and were RP =0.94 and RS =0.94 for Triage vs Singulex, RP =0.93 and RS =0.85 for Triage 
vs PathFast, and RP =0.89 and RS =0.73 for PathFast vs Singulex.
Conclusions: In a single comparative population of ED patients with suspected ACS, the 
Triage Cardio3 TnI, PathFast, and Singulex TnI assays provided similar diagnostic perfor-
mance for MI. 
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INTRODUCTION
Emergency medicine is practiced in a high pressure, high vol-
ume, time-sensitive clinical environment, where the value of 
rapid data acquisition is at a premium. Because early disposi-
tion decision-making in the emergency department (ED) can 
improve outcome and decrease mortality [1-5], processes that 
shorten the time for definitive diagnoses are of value. Point-of-
care (POC) testing, defined as the performance of laboratory 
analyses in a near-patient location, eliminates many of the pre-
and post-analytic sources of delay associated with performance 
in the central laboratory. In previous studies, POC testing de-
creased the time required to provide results to the physician by 
approximately 1 hr [6], and showed a 2-hr reduction in the ED 
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length of stay (ED LOS) in suspected myocardial infarction (MI) 
patients [7]. However, the impact of POC testing, in terms of re-
duced time to results, must be considered in comparison to its 
potential negatives. While POC testing may yield results more 
rapidly than the laboratory-based assays, it has historically been 
generally at the cost of accuracy, compared to the results ob-
tained by the central laboratory. 
The purpose of this study was to compare the diagnostic ac-
curacy of the Triage Cardio3 Troponin I (TnI) (Alere, Inc., San 
Diego, CA, USA) and the PathFast cTnI-II (Mitsubishi Chemical 
Medience Corporation, Tokyo, Japan) POC assays to the Singu-
lex Erenna TnI assay (Alameda, CA, USA) laboratory-based 
platform, by using plasma samples from the Markers in the Di-
agnosis of Acute Coronary Syndromes (MIDAS) study. 
METHODS
MIDAS was a prospective, multi-center, blinded observational 
study that involved plasma samples from adult ED patients pre-
senting with suspected acute coronary syndrome (ACS). It re-
quired that patients had symptoms for at least 10 min, with pre-
sentation and enrollment within 6 hr of symptom onset. MIDAS 
was registered at clinicaltrials.gov as #NCT01134913; the meth-
ods and description have been previously published [8]. This 
study was sponsored by Alere, Inc., and approved by each par-
ticipating institution’s respective institutional review board. All 
participants provided informed consent. The authors had access 
to all data, and the manuscript was drafted by the first author.
Briefly, to be eligible for enrollment in MIDAS, the patient’s 
presenting symptoms had to be such that the ED physician pro-
spectively planned an objective evaluation for myocardial isch-
emia, including testing such as nuclear stress testing. Cardiac 
marker testing alone did not allow patient enrollment. Patient 
outcome for the endpoint MI vs no-MI was determined by three 
independent adjudicators unaffiliated with the MIDAS study 
sites. Adjudicators were provided clinical data summaries and 
completed case report forms, which were used to apply the cri-
teria described in the 2012 publication ESC/ACCF/AHA/WHF 
Expert Consensus Document: Universal Definition of Myocardial 
Infarction [9]. Unanimity among the adjudicators was required 
to assign a diagnosis of MI or no-MI. Adjudicators met to review 
the discrepant cases, and if this collective review determined 
that insufficient information was available to reach unanimity, a 
final diagnosis of “indeterminate” was assigned. Assays were 
evaluated for performance against the adjudicated outcomes.
Venous blood samples were collected in EDTA tube in the ED, 
during the period from 2006 to 2007. Plasma was aliquoted 
into cryotubes and then frozen at -80°C within 1 hr of collection. 
Once frozen, the samples were shipped and analyzed by a core 
laboratory. While the Triage and PathFast assays were both 
tested using the same sample set, the enrollment measure-
ments were not available for all patients; therefore, the actual 
number of analyzable samples differs slightly among Triage and 
PathFast assays. Table 1 lists the analyzable sample sizes. Be-
cause of the limitations in the available sample volume, the Sin-
gulex cohort was numerically smaller. Singulex assay results 
were measured in February 2011, and the Pathfast and Triage 
assay results were measured in September 2013.
To ensure appropriate distribution of diagnoses in the Singu-
lex cohort, we selected a predefined set of 295 samples, which 
were limited to the initial enrollment draw (0 hr), with a mini-
mum of 720 μL of available plasma sample. Seven samples 
from the actual 301 patients were excluded because of the dis-
crepancies between the sample bank volume estimates and the 
actual volume.
For the Triage Cardio3 TnI (Alere, Inc.) assay, the sample was 
treated with fluorescent antibody conjugates flowing through the 
test device by capillary action. The test device was inserted into 
the Triage Meter, and fluorescent signals are measured in ap-
proximately 20 min. Assay performance characteristics are re-
ported in Table 2 [10]. The 99th-percentile of normal control 
subjects and the limit of quantitation (LOQ), defined as the low-
est concentration with <20% CV, are both 20 pg/mL. The val-
ues below the lower limit were set to 10 pg/mL, while those 
Table 1. Gold standard diagnosis distribution for each TnI assay cohort
Diagnosis
Triage (n=968) PathFast (n=989) Singulex (n=288)
(+)* (-) All (+)* (-) All (+)* (-) All
No MI 76 (8.9%) 781 857 64 (7.4%) 822 886 22 (10.3%) 191 213
MI 88 (79.3%) 23 111 79 (76.7%) 24 103 69 (92.0%) 6 75
Total 164 (16.9%) 804 968 143 (14.5%) 846 989 91 (31.6%) 197 288
*Positive defined as ≥20, 29, and 10.2 pg/mL for Triage, Pathfast, and Singulex, respectively. 
Abbreviations: TnI, troponin; MI, myocardial infarction.
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above the upper limit were set to 10,000 pg/mL.
The Mitsubishi PathFast cTnI-II test is a Food and Drug Ad-
ministration (FDA)-approved chemiluminescent enzyme immu-
noassay for use in both clinical laboratory and POC settings. A 
sample is placed on the reagent cartridge and combined with 
antibody-coated magnetic particles and alkaline phosphatase 
conjugate. Troponin-bound complex emits photons, which are 
detected in the PathFast instrument and converted to troponin 
concentrations [11]. Assay performance characteristics are re-
ported in Table 2.
Singulex Erenna TnI concentrations were measured in dupli-
cate by using EDTA plasma specimens (Singulex, Alameda, CA, 
USA). The values below the lower LOQ were set to the lower 
LOQ, while those above the upper LOQ were set to the upper 
LOQ. The Singulex ZeptX System consists of flow immunoas-
says linked to a digital molecule-counting instrument. TnI-spe-
cific antibodies (BiosPacific, Emeryville, CA, USA) are used, and 
the sample is pumped through a glass capillary. Flow and vol-
ume are set such that a single fluorescent molecule passes 
through a laser beam at a time, with the fluorescence detected 
via an optical system coupled to a photon detector, thus provid-
ing high resolution of signal events [11]. Assay performance 
characteristics are reported in Table 2.
Statistical metrics were calculated by using SAS 9.3 (SAS In-
stitute, Cary, NC, USA). Sensitivity, specificity, and predictive 
values were calculated at a clinical cutpoint defined as the 99th 
percentile of concentrations from a normal reference population 
[13]. This value was 20 pg/mL for Triage TnI, 29 pg/mL for 
PathFast, and 10.2 pg/mL for Singulex test, based on the man-
ufacturer’s recommendations [10-12]. The degree of analytical 
correlation tested in samples with detectable troponin levels be-
tween the Triage, PathFast, and Singulex TnI tests was evalu-
ated by using the Pearson and Spearman correlation statistic. 
Only subjects with measured values between the lower and up-
Table 2. Assay performance characteristics
Alere Triage [10] PathFast cTnI [11] Singulex Erenna [12]
LOD N/A (Limit of blank, 10 pg/mL) 8 pg/mL 0.1 pg/mL
LOQ 20 pg/mL 19 pg/mL 0.4 pg/mL
Reportable range 10-10,000 pg/mL 19-50,000 pg/mL 0.4-600 pg/mL
99th percentile 20 pg/mL 29 pg/mL 10.2 pg/mL
CV 16.7% at 60 pg/mL and 11.0% 
at 5,000 pg/mL
6.1% at 29 pg/mL and 3.9% 
at 251 pg/mL
low-end CV% range of 2-8%, 
and low-end CV% average 5%
CV at 99th percentile <20% 5% 9%
Abbreviations: TnI, troponin; N/A, not available; LOD, level of detection; LOQ, level of quantitation.
Table 3. Sensitivity and specificity for AMI with 95% CI for each assay at the enrollment time point 
Performance of AMI detection in a population with detectable TnI (for each assay)
Triage TnI (n=968) PathFast TnI (n=989) Singulex TnI (n=288)
Sensitivity (95% CI) 79.3 (70.5, 86.4) 76.7 (76.4, 84.5) 92.0 (83.4, 97.0)
Specificity (95% CI) 91.1 (89.0, 92.9) 92.8 (90.9, 94.4) 89.7 (84.8, 93.4)
C-Statistics (95% CI) 0.90 (0.86, 0.93) 0.88 (0.84, 0.92) 0.96 (0.93, 0.99)
Triage vs Singulex PathFast vs Singulex Triage vs PathFast 
Comparison P =0.0002, n=74 P <0.0001, n=65 P =0.1770, n=130
Performance of AMI detection in the population common for all assays (n=241)
Sensitivity (95% CI) 89.7 (78.8, 96.1) 89.7 (78.8, 96.1) 89.7 (78.8, 96.1)
Specificity (95% CI) 91.3 (86.2, 94.9) 90.2 (84.9, 94.1) 89.6 (84.3, 93.6)
C-Statistics (95% CI)    0.95 (0.91 to 0.99)    0.93 (0.89 to 0.97)    0.95 (0.91 to 0.99)
Triage vs Singulex PathFast vs Singulex Triage vs PathFast 
Comparisons P =0.8928 P =0.2701 P =0.2142
Positive defined as ≥20, 29, and 10.2 pg/mL for Triage, PathFast, and Singulex, respectively. 
Abbreviations: AMI, acute myocardial infarction; TnI, troponin; CI, confidence interval.
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per limits for both assays in each comparison were included in 
correlation computations (Triage Cardio3: lower=10 pg/mL, up-
per =10,000 pg/mL; PathFast: lower =19 pg/mL, upper = 
50,000 pg/mL, and Singulex Erenna: lower=0.4 pg/mL, up-
per=600 pg/mL.).
Fig. 1. Bland Altman plots of Triage TnI vs Singulex TnI (A), Triage TnI vs PathFast TnI (B), and PathFast TnI vs Singulex TnI (C). Samples 
above or below the measurable range for either assay were excluded.
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RESULTS
The total MIDAS cohort consisted of 1,018 patients of whom 
557 (54.7%) were men, with a mean age of 58 (SD=13.4) yr, 
and a median time of presentation after symptom onset of 1.9 
hr (interquartile rank [IQR]=1.1, 2.9). Overall, 681 (66.9%) pa-
Fig. 2. Passing-Bablok regression plots of Triage TnI vs Singulex TnI (A), Triage TnI vs PathFast TnI (B), and PathFast TnI vs Singulex TnI 
(C). Samples above or below the measurable range for either assay were excluded.
Abbreviation: CI, confidence interval.
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tients were Caucasian, 265 (26.0%) patients were African 
American, 55 (5.4%) patients were Hispanic, and 12 (1.2%) 
patients were Asian. The initial creatinine level exceeded 1.5 
mg/dL in 79 (7.8%) patients. At the index visit, 358 (35.2%) 
patients were discharged from the ED, with the remaining 660 
(64.8%) being hospitalized. Comparison of the overall MIDAS 
population and the PathFast and Singulex cohorts showed no 
significant differences in any demographics or clinical charac-
teristics.
Table 3 shows the statistical performance of all three assays, 
and Fig. 1 shows the Bland Altman plots, and Fig. 2, the Pass-
ing-Bablok Regression, comparing each of the assays. Table 3 
presents the sensitivity and specificity for the three devices at 
the enrollment time point. In the first comparison of Table 3, the 
cohort sizes vary because only those samples with detectable 
troponin levels were included, resulting in the following results; 
Triage vs PathFast (n=130), Triage vs Singulex (n=74), and 
PathFast vs Singulex (n=65). The C-statistic (95% confidence 
interval [CI]) for distinguishing MI from no-MI by using the en-
rollment draw was 0.90 (0.86, 0.93) for the Alere, 0.96 (0.93, 
0.99) for the Singulex, and 0.88 (0.84, 0.92) for the PathFast 
assays. The P values are 0.177 for Triage vs PathFast, 0.0002 
for Triage vs Singulex, and <0.0001 for Pathfast vs Singulex. 
Enrollment draws with detectable troponin levels exhibited high-
to-very-high correlation among the three assay platforms. Pear-
son (RP) and Spearman (RS) correlations, respectively, were RP = 
0.94 and RS =0.94 for Triage vs Singulex, RP =0.93 and RS = 
0.85 for Triage vs PathFast, and RP =0.89 and RS =0.73 for 
PathFast vs Singulex.
The second part of Table 3 shows the results obtained for 241 
samples for which all three assays were performed and resulted 
in C-statistics (95% CI) for each assay’s detection of acute myo-
cardial infarction (AMI) of 0.95 (0.91-0.99), 0.93 (0.89-0.97), 
and 0.95 (0.91-0.99) for the Triage, PathFast, and Singulex as-
says, respectively. Table 4 shows the number of patients show-
ing assay discrepancies. 
DISCUSSION
We have demonstrated that a contemporary POC assay can 
produce results that are statistically equivalent to the recently 
FDA-approved highly sensitive near-patient testing method 
PathFast TnI and the highly sensitive laboratory-based Singulex 
assay when tested in a common cohort. However, when tested 
individually by using the variable-sized enrollment population, 
the Singulex assay had a slightly higher C-statistic value that 
was statistically significant. While the Singulex assay has clearly 
demonstrated excellent performance as a research tool [13, 14] 
and as a comparator in this study, the mechanics of its current 
performance, with a turn-around time measured in days, com-
pletely preclude its routine clinical application. Thus, with regard 
to the POC assays evaluated herein, if available for clinical use, 
these findings may provide practitioners greater opportunity to 
consider POC technology for clinical utility. 
Each year, six million people [16] present to the United States 
EDs with suspected ACS where decisions regarding their ulti-
mate disposition depend on the troponin levels. While a tropo-
nin level exceeding the 99th percentile identifies a patient in 
whom additional evaluation is warranted, an overwhelming ma-
jority of patients presenting with suspected ACS undergo a 
lengthy work-up that is ultimately negative. Recent data suggest 
that rule-out protocols as short as 2 hr [17] could greatly in-
crease the speed to ED discharge in a subset of patients. Our 
results support the use of POC assays for shorter rule-out proto-
cols.
Studies have shown that POC testing decreases the potential 
time-to-clinical decision-making by 1-2 hr [6, 7]. In today’s busy 
EDs and intensive care units (ICUs), the rapid results obtained 
by POC testing have important implications. In fact, a recent re-
port on >13 million ED visits pointed out that prolonged ED LOS 
(defined as >6 hr) is associated with 79% increase in acute 
mortality [1]. Thus, decreasing the LOS  by more rapid disposi-
tion decisions suggests that even the 1-hr advantage offered by 
POC testing has important implications. Conversely, beyond the 
level of disposition decision-making, some studies have sug-
gested that an early invasive strategy (e.g., percutaneous coro-
nary intervention) for selected non-ST segment elevation MI pa-
tients at high pre-test risk for adverse events may even improve 
mortality outcomes. 
Table 4. Details of patients with assay discrepancies
Diagnosis
Patients with results of all 3 assays 
(n=241)
Non-AMI, n=183
   All 3 assays negative 155
   All 3 assays positive 10
   Discrepant results 18
AMI, n=58
   All 3 assays negative 51
   All 3 assays positive 5
   Discrepant results 2
Abbreviation: AMI, acute myocardial infarction.
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This study has several limitations. As a banked sample analy-
sis performed in a central laboratory, it must be considered that 
the POC assay might possess different characteristics when the 
vagaries of the clinical environment are applied. Further, be-
cause the specimens used in this analysis were constructed 
from a sample bank, the clinical performance of the POC testing 
might be affected by the differences in the pre-test ACS proba-
bility when used in a different environment as well as ACS distri-
bution. Moreover, because only the initial troponin test was se-
lected, and because we used a patient population of ACS sus-
pects, the diagnostic accuracy described in this study might not 
reflect the overall performance of these assays in clinical prac-
tice where serial measures are routinely performed. 
It must also be considered that there is no concentration for 
which the Triage assay has a 10% CV. It should be pointed out 
that although guidelines recommend that the optimal CV at the 
99th percentile upper reference limit be ≤10%, they do discuss 
that an assay at ≤20% is acceptable and has utility, while re-
jecting assays with a CV of >20% for clinical use. Ultimately, 
while the troponin values obtained rapidly from POC testing may 
allow earlier disposition, interventions, and greater transfer ac-
curacy, the success of this approach depends on the non-rate-
limiting nature of other processes.
We found that in a large population of suspected ACS pa-
tients, the Singulex assay provided the best statistical discrimi-
nation for the diagnosis of AMI. However, when a single com-
mon population was used for analysis, the Singulex, PathFast, 
and Triage assays were found to have similar diagnostic perfor-
mance.
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